Evidence supporting Sutent of carcinoid cancer is limited. A Phase II study in 2008 concluded that Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this nonrandomized study. AN editorial by Bajetta et al inm teh Journal of CLinical Oncology questioend whetehr results for neuroendocrine cancer can be generalized to the more benign carcinoid subtypes. A randomized trial was announced in January 2010 to show prolongation of survival with Sutent for neuroendocrine cancer and we await the publication of those results.
NCCN on p. 11 of its Neuroendocrine guidelines, the section on carcinoid tumors, does not list Sutent. Emilio Bajetta, Valentina Guadalupi, Giuseppe Procopio, Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors JCO Jan 10, 2009:319-320
Matthew H. Kulke, Heinz-Josef Lenz, Neal J. Meropol, James Posey, David P. Ryan, Joel Picus, Emily Bergsland, Keith Stuart, Lesley Tye, Xin Huang, Jim Z. Li, Charles M. Baum, Charles S. Fuchs Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors JCO July 10, 2008 vol. 26 no. 20 3403-3410 Kulke MH, Lenz H-J, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410, 2008